Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Impact · against what's priced in

The news is marginally positive for Photocure as it outlines two clinical trials that could expand the utility and clinical evidence for Hexvix, but it lacks immediate catalysts. Because these are 'trials in progress' without final data, the actual impact on valuation is limited until primary endpoints are met.

PHO+0.20

No priced-in read yet